儿童急性淋巴细胞白血病初诊特征及其与诱导缓解治疗疗效的关系
Initial Clinical Characteristics of Acute Lymphoblastic Leukemia in Children and Their Relationship with the Efficacy of Induced Remission Therapy
摘要: 目的:分析儿童急性淋巴细胞性白血病(ALL)初诊临床特征及其与诱导缓解化疗后完全缓解率之间的关系,以期为预测以及调整治疗方案提供依据。方法:回顾性分析2015年1月~2020年4月在青岛大学附属医院儿童医学中心确诊的179例ALL患儿的初诊临床资料,并进一步分析其与诱导缓解治疗疗效的关系。结果:179例患儿中,低危组患儿107例,中危组66例,高危组6例,男女比例为1.21:1,平均年龄为4.94岁,中位年龄4.00岁。三组患儿初诊时WBC计数具有显著统计学差异(P < 0.001),Hb、PLT计数无统计学差异(P > 0.05);患儿在LDH水平具有统计学差异(P < 0.05),在血清SF水平无显著差异(P > 0.05)。白血病相关融合基因检出率为31.46%。179患儿全部完成诱导缓解化疗,d19天MRD缓解率为73.18%,d46天MRD缓解率为83.24%。患儿初诊时的年龄、WBC计数、LDH水平与d46天MRD缓解率具有相关性。结论:初诊ALL患儿的初诊临床特征与不同研究中心存在异同,年龄、WBC计数及LDH水平与诱导缓解化疗后MRD缓解率之间具有相关性。
Abstract: Objective: To Analyze the relationship between the clinical characteristics of children with acute lymphoblastic leukemia (ALL) at initial diagnosis and the rate of complete response after induced remission chemotherapy, so as to provide a basis for prognosis prediction and treatment adjustment. Methods: The clinical data of 179 children with ALL diagnosed in Children’s Medical Center, Affiliated Hospital of Qingdao University from January 2015 to April 2020 were retrospectively analyzed, and their relationship with the curative effect of induced remission therapy was further analyzed. Results: Among the 179 cases, 107 were in the medium-low risk group, 66 were in the medium-risk group, and 6 were in the high-risk group. The male to female ratio was 1.21:1, the average age was 4.94 years, and the median age was 4.00 years. There were significant differences in WBC count (P < 0.001), but no significant differences in Hb and PLT count (P > 0.05). There was statistical difference in LDH level (P < 0.05), but no significant difference in serum SF level (P > 0.05). The detection rate of leukemia-related fusion gene was 31.46%. All 179 children completed the induction of remission chemotherapy, and the MRD remission rate was 73.18% at d19 day and 83.24% at d46 day. Age at first diagnosis, WBC count and LDH level were correlated with the remission rate of MRD at d46 day. Conclusion: There are similarities and differences in the clinical features and characteristics of newly diagnosed ALL children with different study centers. Age, WBC count and LDH level are correlated with MRD response rate after induction of remission chemotherapy.
文章引用:徐晓莲, 卢愿. 儿童急性淋巴细胞白血病初诊特征及其与诱导缓解治疗疗效的关系[J]. 临床医学进展, 2022, 12(4): 2953-2960. https://doi.org/10.12677/ACM.2022.124426

参考文献

[1] Pui, C.H., Yang, J.J., Hunger, S.P., Pieters, R., Schrappe, M., Biondi, A., et al. (2015) Childhood Acute Lymphoblastic Leukemia: Progress through Collaboration. Journal of Clinical Oncology, 33, 2938-2948. [Google Scholar] [CrossRef
[2] 兰洋, 陈晓娟, 邹尧, 阮敏, 竺晓凡. CCLG-ALL2008方案治疗10岁以上儿童及青少年急性淋巴细胞白血病的疗效分析[J]. 中国当代儿科杂志, 2019, 21(5): 405-410.
[3] 蔡娇阳, 王宁玲, 蒋慧, 沈树红, 薛惠良, 陈静, 等. 儿童急性淋巴细胞白血病2005方案多中心远期临床报告[J]. 中华儿科杂志, 2018, 56(7): 511-517.
[4] Radu, L.E., Colita, A., Pasca, S., Tomuleasa, C., Popa, C., Serban, C., et al. (2020) Day 15 and Day 33 Minimal Residual Disease Assessment for Acute Lymphoblastic Leukemia Patients Treated According to the BFM ALL IC 2009 Protocol: Single-Center Experience of 133 Cases. Frontiers in Oncology, 10, Article No. 923. [Google Scholar] [CrossRef] [PubMed]
[5] Landau, H. and Lamanna, N. (2006) Clinical Manifestations and Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Adults. Current Hematologic Malignancy Reports, 1, 171-179. [Google Scholar] [CrossRef] [PubMed]
[6] Koukourakis, M.I., Giatromanolaki, A. and Sivridis, E. (2003) Lactate Dehydrogenase Isoenzymes 1 and 5: Differential Expression by Neoplastic and Stromal Cells in Non-Small Cell Lung Cancer and Other Epithelial Malignant Tumors. Tumor Biology, 24, 199-202. [Google Scholar] [CrossRef] [PubMed]
[7] 吴永霞, 王海燕, 王伟. 骨髓增生异常综合征和急性白血病病人血清TPO、LDH的测定及临床意义[J]. 中国实验血液学杂志, 2010, 18(3): 671-674.
[8] Miao, P., Sheng, S., Sun, X., Liu, J. and Huang, G. (2013) Lactate Dehydrogenase A in Cancer: A Promising Target for Diagnosis and Therapy. IUBMB Life, 65, 904-910. [Google Scholar] [CrossRef] [PubMed]
[9] Benadiba, J., Rosilio, C., Nebout, M., Heimeroth, V., Neffati, Z., Popa, A., et al. (2017) Iron Chelation: An Adjuvant Therapy to Target Metabolism, Growth and Survival of Murine PTEN-Deficient T Lymphoma and Human T Lymphoblastic Leukemia/Lymphoma. Leukemia & Lymphoma, 58, 1433-1445. [Google Scholar] [CrossRef] [PubMed]
[10] Hagag, A.A., Badraia, I.M., Abdelmageed, M.M., Hablas, N.M., Hazzaa, S.M.E. and Nosair, N.A. (2018) Prognostic Value of Transferrin Receptor-1 (CD71) Expression in Acute Lymphoblastic Leukemia. Endocrine, Metabolic & Immune Disorders-Drug Targets, 18, 610-617. [Google Scholar] [CrossRef] [PubMed]
[11] 刘青, 蒋慧, 孙恒娟, 宋以菊, 包黎明. 儿童急性淋巴细胞白血病细胞遗传学特征分析[J]. 中华血液学杂志, 2012, 33(4): 282-285.
[12] 张小珍, 乐萍, 霍小春, 黄慧, 黎文婷, 郭智彬. 178例儿童急性淋巴细胞白血病细胞与分子遗传学特征研究[J]. 中国优生与遗传杂志, 2014, 22(9): 33-35+49.
[13] Rubnitz, J.E., Wichlan, D., Devidas, M., Shuster, J., Linda, S.B., Kurtzberg, J., et al. (2008) Prospective Analysis of TEL Gene Rearrangements in Childhood Acute Lymphoblastic Leukemia: A Children’s Oncology Group Study. Journal of Clinical Oncology, 26, 2186-2191. [Google Scholar] [CrossRef
[14] 高静, 胡绍燕, 卢俊, 何海龙, 王易, 赵文理, 等. TEL/AML1基因阳性急性淋巴细胞白血病患儿CCLG-ALL-2008方案疗效分析[J]. 临床儿科杂志, 2017, 35(5): 325-330.
[15] Ismail, S.I., Naffa, R.G., Yousef, A.M. and Ghanim, M.T. (2014) Incidence of bcr-abl Fusion Transcripts in Healthy Individuals. Molecular Medicine Reports, 9, 1271-1276. [Google Scholar] [CrossRef] [PubMed]
[16] Gao, C., Zhao, X.X., Li, W.J., Cui, L., Zhao, W., Liu, S.G., et al. (2012) Clinical Features, Early Treatment Responses, and Outcomes of Pediatric Acute Lymphoblastic Leukemia in China with or without Specific Fusion Transcripts: A Single Institutional Study of 1,004 Patients. American Journal of Hematology, 87, 1022-1027. [Google Scholar] [CrossRef] [PubMed]
[17] Rives, S., Estella, J., Gómez, P., López-Duarte, M., de Miguel, P.G., Verdeguer, A., et al. (2011) Intermediate Dose of Imatinib in Combination with Chemotherapy Followed by Allogeneic Stem Cell Transplantation Improves Early Outcome in Paediatric Philadelphia Chromosome-Positive Acute Lymphoblastic Leukaemia (ALL): Results of the Spanish Cooperative Group SHOP Studies ALL-94, ALL-99 and ALL-2005. British Journal of Haematology, 154, 600-611. [Google Scholar] [CrossRef] [PubMed]
[18] Tomizawa, D., Kato, M., Takahashi, H., Fujimura, J., Inukai, T., Fukushima, T., et al. (2015) Favorable Outcome in Non-Infant Children with MLL-AF4-Positive Acute Lymphoblastic Leukemia: A Report from the Tokyo Children’s Cancer Study Group. International Journal of Hematology, 102, 602-610. [Google Scholar] [CrossRef] [PubMed]
[19] 张琳琳. E2 A-PBX1融合基因阳性儿童急性淋巴细胞白血病发病机制及复发相关因素[J]. 国际儿科学杂志, 2018, 45(10): 776-778+782.
[20] Pui, C.H., Sandlund, J.T., Pei, D., Campana, D., Rivera, G.K., Ribeiro, R.C., et al. (2004) Improved Outcome for Children with Acute Lymphoblastic Leukemia: Results of Total Therapy Study XIIIB at St Jude Children’s Research Hospital. Blood, 104, 2690-2696. [Google Scholar] [CrossRef] [PubMed]
[21] Jovanovska, A., Martinova, K., Kocheva, S., Trajkova-Antevska, Z., Coneska-Jovanova, B., Panovska-Stavridis, I., et al. (2019) Clinical Significance of Minimal Residual Disease at the End of Remission Induction Therapy in Childhood Acute Lymphoblastic Leukemia. Open Access Macedonian Journal of Medical Sciences, 7, 2818-2823.
[22] Wei, W., Chen, X., Zou, Y., Chang, L., An, W., Wan, Y., et al. (2015) Prediction of Outcomes by Early Treatment Responses in Childhood T-Cell Acute Lymphoblastic Leukemia: A Retrospective Study in China. BMC Pediatrics, 15, Article No. 80. [Google Scholar] [CrossRef] [PubMed]